This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

Spotting Red Flags: Understanding how Biotech Top Line Press Releases about FDA Meetings Can "Trick" Investors.

Ticker(s): IBB

Who's the expert?

A former FDA regulatory official who has worked at the agency and interacted with pharmaceutical companies previously.

Interview Goal
This conversation will be a tutorial of sorts for investors. The expert and call leader will explore various ways the management teams can massage data or press releases in the face of less than stellar results. 

This conversation will pull real life examples of press releases and delays to illustrate issues. 

Are You Interested In These Questions?



72Days Left to Join Project

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.